new_0222_0420|AVTE|Short Name|0|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment
new_0222_0420|AVTE|Long Name|1|1|Aerovate Therapeutics Inc Total Current Assets (Quarterly) (USD)|Aerovate Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Aerovate Therapeutics Inc Inventories (Quarterly) (USD)|Aerovate Therapeutics Inc Net PP&E (Quarterly) (USD)|Aerovate Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Aerovate Therapeutics Inc Total Liabilities (Quarterly) (USD)|Aerovate Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Aerovate Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Aerovate Therapeutics Inc Total Deposits (Quarterly) (USD)|Aerovate Therapeutics Inc Book Value (Quarterly) (USD)|Aerovate Therapeutics Inc Retained Earnings (Quarterly) (USD)|Aerovate Therapeutics Inc Treasury Stock (Quarterly) (USD)|Aerovate Therapeutics Inc EV to Revenues|Aerovate Therapeutics Inc EV to Earnings|Aerovate Therapeutics Inc EV to Free Cash Flow|Aerovate Therapeutics Inc EV to Assets (Quarterly)|Aerovate Therapeutics Inc PS Ratio|Aerovate Therapeutics Inc PE Ratio|Aerovate Therapeutics Inc Price to Book Value|Aerovate Therapeutics Inc PEG Ratio|Aerovate Therapeutics Inc Debt to Equity Ratio|Aerovate Therapeutics Inc Dividend Yield|Aerovate Therapeutics Inc Shareholder Yield (TTM)|Aerovate Therapeutics Inc Percent of Shares Outstanding Short|Aerovate Therapeutics Inc Total Receivables (Quarterly) (USD)|Aerovate Therapeutics Inc Total Payables (Quarterly) (USD)|Aerovate Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Aerovate Therapeutics Inc Return on Invested Capital|Aerovate Therapeutics Inc Quality Ratio Score|Aerovate Therapeutics Inc Momentum Score|Aerovate Therapeutics Inc Beta (1Y)|Aerovate Therapeutics Inc Sustainable Growth Rate (TTM)|Aerovate Therapeutics Inc Institutional Investor Ownership Percentage|Aerovate Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Aerovate Therapeutics Inc Total Employees (Annual)|Aerovate Therapeutics Inc EPS Diluted (Quarterly) (USD)|Aerovate Therapeutics Inc SG&A Expense (Quarterly) (USD)|Aerovate Therapeutics Inc Shares Outstanding|Aerovate Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Aerovate Therapeutics Inc Ordinary Shares Number (Quarterly)|Aerovate Therapeutics Inc Payout Ratio|Aerovate Therapeutics Inc Quick Ratio (Quarterly)|Aerovate Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Aerovate Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Aerovate Therapeutics Inc Effective Tax Rate (TTM)|Aerovate Therapeutics Inc Return on Equity|Aerovate Therapeutics Inc Net Income (TTM) (USD)|Aerovate Therapeutics Inc Revenue (TTM) (USD)|Aerovate Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Aerovate Therapeutics Inc Revenue (Quarterly) (USD)|Aerovate Therapeutics Inc Gross Profit (Quarterly) (USD)|Aerovate Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Aerovate Therapeutics Inc Net Income (Quarterly) (USD)|Aerovate Therapeutics Inc Net Interest Income (Quarterly) (USD)|Aerovate Therapeutics Inc Price (USD)|Aerovate Therapeutics Inc Total Return Price (USD)|Aerovate Therapeutics Inc Enterprise Value (USD)|Aerovate Therapeutics Inc 30-Day Average Daily Volume|Aerovate Therapeutics Inc 1 Year Price Returns (Daily)|Aerovate Therapeutics Inc Short Interest|Aerovate Therapeutics Inc PE Ratio (Forward)|Aerovate Therapeutics Inc PE Ratio (Forward 1y)|Aerovate Therapeutics Inc PS Ratio (Forward)|Aerovate Therapeutics Inc PS Ratio (Forward 1y)|Aerovate Therapeutics Inc Quarterly EPS Estimates (USD)|Aerovate Therapeutics Inc Quarterly Revenue Estimates (USD)|Aerovate Therapeutics Inc Quarterly EPS Surprise|Aerovate Therapeutics Inc Quarterly Revenue Surprise|Aerovate Therapeutics Inc Quarterly Actual EPS (USD)|Aerovate Therapeutics Inc Quarterly Actual Revenue (USD)|Aerovate Therapeutics Inc Revenue Estimates for Current Fiscal Year (USD)|Aerovate Therapeutics Inc Revenue Estimates for Next Fiscal Year (USD)|Aerovate Therapeutics Inc Price Target (USD)|Aerovate Therapeutics Inc Consensus Recommendation|Aerovate Therapeutics Inc Price Target Num Estimates|Aerovate Therapeutics Inc EPS Estimates for Current Fiscal Year (USD)|Aerovate Therapeutics Inc EPS Estimates for Next Fiscal Year (USD)|Aerovate Therapeutics Inc Research and Development Expense (Quarterly) (USD)|Aerovate Therapeutics Inc Reconciled Depreciation (Quarterly) (USD)|Aerovate Therapeutics Inc Non-Operating Interest Expense (Quarterly) (USD)|Aerovate Therapeutics Inc Land and Improvements (Quarterly) (USD)|Aerovate Therapeutics Inc Buildings and Improvements (Quarterly) (USD)|Aerovate Therapeutics Inc Other Properties (Quarterly) (USD)|Aerovate Therapeutics Inc Machine, Furniture & Equipment (Quarterly) (USD)
new_0222_0420|AVTE|Unit|2|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric
new_0222_0420|AVTE||4|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly
new_0222_0420|AVTE||5|5|91|91|0|91|0|91|91|91|0|91|91|0|0|0|1.43827160494|0|0|0|1.4387755102|0|0|1.43827160494|0|15.3571428571|0|91|91|0|0|0|0|0|0|91.3333333333|50|91.3333333333|91.3333333333|28.2|0|91|0|0|91.3333333333|91.25|0|0|91|0|0|0|0|91.3333333333|91.3333333333|91.3333333333|1.43827160494|1.43827160494|1.43827160494|1.43609022556|0|15.3571428571|0|0|0|0|91.5|91.5|92|0|92|92|33.3333333333|22.2222222222|18.8181818182|15.9230769231|18.8181818182|39.8|28.5714285714|91.3333333333|91.3333333333|91.25|0|0|91|0
new_0222_0420|AVTE||6|6|3|3|0|3|0|3|3|3|0|3|3|0|0|0|162|0|0|0|98|0|0|162|0|14|0|3|3|0|0|0|0|0|0|6|2|6|6|5|0|3|0|0|6|4|0|0|3|0|0|0|0|6|6|6|162|162|162|133|0|14|0|0|0|0|6|6|1|0|1|1|6|9|11|13|11|5|7|6|6|4|0|0|3|0
new_0222_0420|AVTE||7|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly
new_0222_0420|AVTE|202003|202003|202003||||||||||||||||||||||||||||||||||4.4967||-0.3193|0.152||||||-0.3193|||||||||-1.436|-1.436|-0.038||||||||||||||||||||||||1.206|0|0.038||||
new_0222_0420|AVTE|202006|202006|202006||||||||||||||||||||||||||||||||||4.4967||-0.4897|0.154||||||-0.4897|||||||||-2.202|-2.202|-0.037||||||||||||||||||||||||1.471|0|||||
new_0222_0420|AVTE|202009|202009|202009||||||||||||||||||||||||||||||||||4.4967||-0.5471|0.277||||||-0.513|0||||||||-2.307|-2.307|0||||||||||||||||||||||||1.966|0|||||
new_0222_0420|AVTE|202012|202012|202012|4.676|4.573||0.039||18.059|1.774|16.285||-13.344|-13.407|||||||||||||||0.618|0|||||||4.4967||-0.8153|0.366|||23.1081|||-0.8153||||-9.611|||||-3.666|-3.666|0||||||||||||||||||||||||3.297|0.001||||0.04|
new_0222_0420|AVTE|202103|202103|202103|9.604|8.641||0.037||26.063|1.782|24.281||-16.115|-16.201|||||||||||||||1.55|0|||||||4.4967||-0.62|0.584|||23.1081|||-0.62||||-10.956|||||-2.781|-2.781|0||||||||||||||||||||||||2.196|0.002|0|||0.04|
new_0222_0420|AVTE|202106|202106|202106|59.309|59.15||0.035||84.012|4.193|79.819||-21.578|-21.985||||-35.7645|||||||0||0||3.042|0||||||86.4977|23.1081|8|-0.2503|1.447|23.1081||23.1081|||-0.2503||||-14.529|||||-5.775|-5.775|0.002|22.83|22.83|468.4079|||0|||||-0.1|0|-136.6||-0.2366|0||||||||4.327|0.002||||0.04|
new_0222_0420|AVTE|202107|202106|202106|||||||||||||||-19.4337|||||||0||2.6637||||||||||||||24.4104|||||||||||||||||12.85|12.85|254.5236|||650229|||||||||||0|0|24.6667|1|3|-0.41|-2.54|||||||
new_0222_0420|AVTE|202108|202106|202106|||||||||||||||-27.3363|||||||0||3.0637||||||||||||||24.4104|||||||||||||||||17.09|17.09|358.0237|73561.3667||747857||||||||||||0|24.6667|1|3|-0.63|-2.61|||||||
new_0222_0420|AVTE|202109|202109|202109|183.102|180.878||0.745||4.277|3.825|0.452||179.848|-28.169||||-19.2701||||2.8476|||0||4.5614||2.555|0.002|||||||23.885|8|-0.26|2.782|24.4104||24.4104|||-0.26|-127.195|||-18.406|||||-6.184|-6.184|0.016|20.98|20.98|331.2522|181950.6||1113463|||||-0.16|0|-62.5||-0.26|0||0|24.6667|1|3||-2.61|3.418|0.003||||0.745|
new_0222_0420|AVTE|202110|202109|202109|||||||||||||||-12.0989||||2.1621|||0||1.5413|||||||||||||||||||||||||||||||15.93|15.93|207.9797|161511.4333||376240||||||||||||||||||||||||
new_0222_0420|AVTE|202111|202109|202109|||||||||||||||-8.9464||||1.8608|||0||1.5552||||||||||||||24.4104|||||||||||||||||13.71|13.71|153.7886|83824.0333||379623|||||||||||0|0|24.6667|1|3|-0.86|-2.785|||||||
new_0222_0420|AVTE|202112|202112|202112|||||||||||||||-6.2199||||1.6002|||0||1.8277|||||||||||||||||||||||||||||||11.79|11.79|106.9206|88040.9333||446146|||||-0.26|0|||||0|0|24.6667|1|3|-1.29|-2.785|||||||
new_0222_0420|AVTE|202201|202112|202112|||||||||||||||-6.2625||||1.6043|||0||1.7529|||||||||||||||||||||||||||||||11.82|11.82|107.6529|53826.1333||427886|||||||||||||24.6667|1|3|||||||||
new_0222_0420|AVTE|202202|202112|202112|||||||||||||||-1.7468||||1.1727|||0|||||||||||||||||||||||||||||||||8.64|8.64|30.0279|34149.2333|||||||||||||0|0|24.5|1|4|-2.2167|-1.1933|||||||
new_0222_0420|AVTE|202203|202203|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.26|0||||||||||||||||||
new_0222_0420|AVTE|202206|202206|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.265|0||||||||||||||||||
new_0222_0420|AVTE|202209|202209|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.265|0||||||||||||||||||
new_0222_0420|AVTE|202212|202212|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.27|0||||||||||||||||||